Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-274P is a pseudogene corresponding to the U6 small nuclear RNA gene family. Pseudogenes like RNU6-274P arise from retrotransposition events mediated by LINE-1 (L1) elements, resulting in non-functional genomic copies of snRNAs. U6 snRNA itself is a highly conserved and essential component of the spliceosome, involved in mRNA splicing in eukaryotes, but pseudogene copies such as RNU6-274P are not transcribed into functional molecules. The prevalence of U6 snRNA pseudogenes is indicative of their evolutionary importance and the activity of retrotransposition in the genome. RNU6-274P has no known biological activity, disease association, drug interaction, or biomarker utility beyond potential use in studying retrotransposon history.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 274, pseudogene (RNU6-274P).